Loading clinical trials...
Loading clinical trials...
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphom...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ruijin Hospital
NCT06352242 · Diffuse Large B Cell Lymphoma
NCT04889716 · Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
NCT07523737 · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more
Ruijin Hospital
Shanghai, Shanghai Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions